DxTerity Earns SOC 2 Type 2 Compliance, Reinforcing Commitment to Secure Healthcare Data. Read more
 
DxTerity Logo

IFN-1 Test for Lupus

WHITE PAPER

Two new lupus therapies target the influential IFN-1 pathway

  • The key role of IFN-1 in the progression of lupus
  • How a patient’s IFN-1 status may affect response to standard therapy
  • Specific mechanisms of action of 2 new therapies that interrupt the IFN-1 pathway
  • Studies and data featuring patient response to belimumab and anifrolumab
img white paper 1 thumbnail

Better health management begins
at home

Subscribe to receive the latest information on new developments and products at DxTerity.